13 results about "Mucosal disease" patented technology

The invention discloses a traditional Chinese medicine tea drink for preventing and treating oral mucosa diseases and a preparation method of the traditional Chinese medicine tea drink. The traditional Chinese medicine tea drink is prepared from 10-15 parts of radix astragali, 8-12 parts of radix codonopsis, 6-10 parts of radix salviae miltiorrhizae, 5-9 parts of radix angelicae sinensis, 3-6 parts of fructus psoraleae, 6-9 parts of rhizoma polygonati, 6-9 parts of radix adenophorae, 6-10 parts of rhizoma atractylodis macrocephalae, 5-9 parts of radix ophiopogonis, 3-5 parts of radix glycyrrhizae, 4-6 parts of pericarpium citri reticulatae and 5-8 parts of herba taraxaci. Aiming at the core pathogenesis of low immunity, long-term deficiency, long-term deficiency and kidney-yang insufficiency of patients suffering from oral mucosa diseases, qi tonifying, blood activating and kidney-qi strengthening are taken as a core treatment method, the formula is scientific and reasonable, all the medicinal materials act synergistically, the overall immune function of the body is adjusted, T lymphocyte subpopulation imbalance and cell factor network disorder are improved, and the curative effect is good. The oral mucosa microcirculation is improved, local inflammation is relieved, the immunity of a patient is improved fundamentally, the recurrence rate of oral mucosa diseases is reduced, and the problems that an existing tea drink is not high in pertinence and limited in curative effect are solved. The tea drink is appropriate in taste, good in compliance, high in safety and suitable for people with various oral mucosa diseases and low immunity.

The present invention relates to a pharmaceutical composition for preventing or treating nasal mucosa diseases, containing a high concentration of oxygen. Specifically, when administered in the form of a nasal drop solution, aerosol spray, ointment, or gel, the composition of the present invention can continuously deliver high-concentration oxygen directly to the nasal mucosa and enhance ciliary movement. In addition, the composition exhibits an effect of promoting wound healing or inhibiting inflammation through improvement of ciliary motion of the nasal mucosa, and thus can be widely used for preventing or treating burns, infections, inflammations, and nasal mucosa diseases that may occur after nasal surgery.

The invention relates to the technical field of medicine, in particular to polypeptide and application thereof in preparation of medicine for treating oral mucosa diseases. The polypeptide disclosed by the invention can be used for treating recurrent aphthous oral ulceration and oral mucositis caused by anti-tumor treatment. The polypeptide disclosed by the invention has a remarkable treatment effect, can promote ulcer healing, and is dose-dependent and time-dependent; the polypeptide is high in safety, a degradation product is natural amino acid, and the polypeptide has a wide application prospect.

Provided is a peptide compound comprising the amino acid sequence: Xaa1-Lys-Xaa3-Ser-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13 wherein: Xaa1 represents Ala or Ser, or is absent, wherein the N-terminal amino acid optionally includes an N-terminal 3,4-dihydrocinnamic acid group; Xaa5 represents Tyr, DOPA or a single bond; Xaa3 and Xaa6 independently represent Pro, Hyp or diHyp; Xaa7, Xaa8, Xaa9, Xaa10, and Xaa11 are each optional (in which case Xaa6 is bonded to Xaa12), and are independently selected from the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Xaa12 represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Xaa13 represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compound, provided that when the N-terminal 3,4-dihydrocinnamic acid group is not present, Xaa1 represents Ala or is absent and Xaa13 represents Lys, then Xaa12 represents Pro, Hyp, diHyp or Thr. The compounds are particularly useful in for treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynaecological diseases and dental diseases.

There is provided a compound of formula (I), A-Q-B (I) wherein Q represents a structural fragment of formula (II), wherein: the squiggly lines and m have meanings given in the description, and wherein A and B have meanings given in the description, but may represent a peptide component of the amino acid sequence: [(W)m-Lys-X1-T- (U)m- (X2)m- (Y)m]n- (W)m-Lys-X1-T- (U)m- (X2)m- (Y)m (SEQ ID No: 1); wherein n, m, T, W, X1, U, X2 and Y have meanings given in the description, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynaecological diseases and dental diseases.

The invention relates to an antibody or antigen binding fragment thereof which is capable of binding to CD1a. The antibody or antigen binding fragment thereof may be chimeric or humanised, and may be used to treat one or more inflammatory skin or mucosal disorder, or disease or one or more associated systemic disease or disorder, or one or more inflammatory drug reaction which manifests systemically, or a CD1a-expressing malignancy.

This invention relates to the field of antimicrobial peptide technology, specifically to an antimicrobial peptide for maintaining oral flora balance, its preparation method, and its application. The antimicrobial peptide for maintaining oral flora balance according to this invention includes any one of the following polypeptides (a)-(e): (a) a polypeptide whose amino acid sequence includes the amino acid sequence shown in SEQ ID NO. 1; (b) an amino acid sequence composed of amino acid residues shown in SEQ ID NO. 1; (c) a polypeptide formed by substituting and / or deleting and / or adding one or more amino acid residues to the amino acid sequence defined in (a) or (b); (d) a polypeptide having 99% or more, 95% or more, 90% or more, 85% or more, or 80% or more homology to the amino acid sequence defined in (a) or (b); (e) a polypeptide obtained by modifying the N-terminus and / or C-terminus of any one of the polypeptides defined in (a)-(d). The antimicrobial peptides of this invention, used to maintain oral flora balance, exhibit antibacterial and bactericidal activity against oral pathogens while not affecting the normal growth of beneficial bacteria. This balance is maintained, protecting gum health and freshening breath. These antimicrobial peptides are suitable for preparing oral antibacterial agents and related oral care products, regulating the balance of the oral microecology, and thus used to prevent and treat oral diseases, especially dental caries, periodontitis, oral mucosal diseases, and oral cancer. The antimicrobial peptides of this invention are relatively short, making chemical synthesis easier and allowing for direct synthesis into high-purity products. They also exhibit clear effects and have wide applications.

The present invention aims to provide a medicament capable of treating and / or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and / or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

This application relates to the field of nanomedicine technology, and in particular to a selenium-containing nanoparticle, its preparation method, and its application in drugs for treating inflammatory mucosal diseases. The selenium-containing nanoparticle has a core comprising zero-valent selenium or ferrous selenide, and a shell comprising at least one of polyserotonin, dopamine, and sodium alginate; the two are bonded together by C-Se covalent bonds to form a stable organic-inorganic nanocomposite. This selenium-containing nanoparticle overcomes the bottlenecks of traditional selenium nanoparticles, such as easy aggregation and poor retention, and achieves synergistic enhancement of antioxidant, anti-inflammatory, and antibacterial functions. When applied to the treatment of inflammatory mucosal diseases, it can effectively treat inflammatory mucosal diseases in complex environments, such as oral mucositis, based on the "seed-soil" synergistic treatment concept, by synergistically regulating the triple mechanism of "epithelial cells (seeds)," "immune microenvironment (soil)," and "local flora."

The present invention relates to a composition comprising as active ingredients an extract of Cetraria islandica, silver and / or a salt thereof and hyaluronic acid and / or a salt thereof. The present invention further relates to the use of such composition for the treatment of skin and / or mucous membrane diseases.

Aspects of the present disclosure generally relate to a new class of compounds, and compositions thereof, for treating a mucosal disease or symptom thereof in a patient. Aspects of the present disclosure also generally relate to methods of treating a mucosal disease or symptom thereof in a patient using the new class of compounds and compositions thereof. In an aspect, a composition for treating a mucosal disease or symptom thereof in a patient is provided. The composition includes a short chain fatty acid, or an anion, salt, ester, or prodrug thereof, the short chain fatty acid comprising a carbon chain and a carboxylic acid group, the carbon chain plus the carbon atom of the carboxylic acid group having from 2 carbon atoms to 6 carbon atoms.

The invention discloses a traditional Chinese medicine compound decoction for treating oral mucosa diseases, belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound decoction for treating oral mucosa diseases, which is suitable for oral ulcer, oral lichen planus, herpes stomatitis and other mucosa lesions. The core innovation points are as follows: radix bupleuri and radix scutellariae synergistically sooth the liver and clear heat, prepared rehmannia root and angelica sinensis promote mucous membrane repair, white peony root and ligusticum wallichii regulate immune balance, and ginger and jujube enhance anti-oxidation defense. Decoction parameters are strictly limited in the preparation process, loss of effective components is avoided, addition of chemical auxiliary materials is forbidden, and the completeness of the medicine effect is ensured. According to the prescription, through a multi-target-point synergistic effect, mucosa inflammation is rapidly relieved, ulcer healing is accelerated, and the recurrence frequency is remarkably reduced. Clinical verifications prove that the total effective rate of cases with the disease course of more than or equal to 3 months and the recurrence of more than or equal to 2 times per month is more than or equal to 90%, the safety is high, and mucous membrane stimulation or systematic side effects are avoided.

The invention discloses a method for rapidly testing the inactivation of a bovine viral diarrhea / mucosal disease bivalent inactivated vaccine, and relates to the field of veterinary biological products. According to the rapid detection method disclosed by the invention, whether the virus is completely inactivated or not is monitored by detecting different cDNA (complementary deoxyribonucleic acid) gene segments of type 1 and type 2 BVDV, and the specific steps are as follows: extracting total RNA (ribonucleic acid) from the inactivated BVDV, removing DNA residues, carrying out reverse transcription, respectively carrying out PCR (polymerase chain reaction) detection aiming at the type 1 BVDV E2 gene and the type 2 BVDV non-structural protein gene, and judging whether the virus is completely inactivated or not according to an electrophoresis result. According to the method, the type 1 BVDV and the type 2 BVDV can be rapidly detected after being inactivated, whether the BVDV is completely inactivated or not can be determined within 2 hours, the operation procedure of inactivation detection in the bivalent vaccine preparation process is simplified, the detection period is shortened, the cost is saved, and the inactivation detection sensitivity and the vaccine production efficiency are improved.